INDP

+ Watchlist + Portfolio

Indaptus Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.94
52-Week Range: $0.92 – $8.57
Market Cap: $183.87M
P/E (TTM): —
EPS (TTM): -5.17
Dividend Yield: —

Advanced Metrics

Price/Book: 125.45
PEG Ratio: —
Return on Equity: -318.04%
Return on Assets: -98.08%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 19.48
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-9.41M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $113.69M

INDP Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$6.32M	$7.62M	$7.25M	$9.34M
Selling, General & Admin	$8.59M	$8.76M	$8.11M	$10.49M
Operating Expenses	$14.91M	$16.38M	$15.37M	$19.83M
Operating Income	-$14.91M	-$16.38M	-$15.37M	-$19.83M
EBITDA	-$14.91M	-$16.38M	-$15.37M	-$19.83M
Pretax Income	-$14.32M	-$15.42M	-$15.02M	-$20.85M
Net Income	-$14.32M	-$15.42M	-$15.02M	-$20.85M
Diluted EPS	-48.44	-51.24	-45.08	-21.58
Diluted Shares	295075	300037	334132	966124

INDP Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$9.63M	$13.36M	$5.79M	$8.51M
Receivables	$0.00	—	—	—
Current Assets	$27.24M	$14.00M	$6.62M	$9.31M
Total Assets	$28.06M	$14.92M	$7.34M	$9.31M
Current Liabilities	$3.43M	$2.77M	$3.39M	$6.16M
Total Debt	$80.49K	$175.05K	$84.16K	$0.00
Total Liabilities	$3.43M	$2.85M	$3.39M	$6.16M
Retained Earnings	-$29.99M	-$45.42M	-$60.44M	-$81.29M
Shareholders' Equity	$24.63M	$12.08M	$3.94M	$3.15M
Working Capital	$23.81M	$11.22M	$3.22M	$3.15M

INDP Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$13.08M	-$13.41M	-$12.32M	-$14.82M
Free Cash Flow	-$13.08M	-$13.41M	-$12.32M	-$14.82M
Depreciation & Amortisation	$1.78K	$1.28K	$735.00	$0.00
Stock-Based Compensation	$2.96M	$2.97M	$2.31M	$1.36M
Investing Cash Flow	-$16.43M	$17.14M	$0.00	—
Financing Cash Flow	$0.00	$0.00	$4.75M	$17.54M
Net Change in Cash	-$29.51M	$3.74M	-$7.58M	$2.72M

INDP Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$2.81M	$2.17M	$1.52M	$2.85M	$491.13K
Selling, General & Admin	$1.76M	$2.29M	$1.13M	$5.31M	$1.67M
Operating Expenses	$4.57M	$4.46M	$2.65M	$8.16M	$2.16M
Operating Income	-$4.57M	-$4.46M	-$2.65M	-$8.16M	-$2.16M
EBITDA	-$4.57M	-$4.46M	-$2.65M	-$8.16M	-$2.16M
Pretax Income	-$4.53M	-$5.23M	-$2.98M	-$8.11M	-$2.54M
Net Income	-$4.53M	-$5.23M	-$2.98M	-$8.11M	-$2.54M
Diluted EPS	-9.11	-9.09	-2.98	—	-0.23
Diluted Shares	497794	574923	997038	—	10.96M

INDP Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$3.89M	$6.16M	$5.83M	$8.51M	$1.50M
Current Assets	$4.96M	$6.41M	$6.44M	$9.31M	$2.18M
Total Assets	$5.41M	$6.84M	$6.84M	$9.31M	$2.18M
Current Liabilities	$2.61M	$8.51M	$2.23M	$6.16M	$933.00K
Total Debt	$59.51K	$6.54M	$8.69K	$0.00	—
Total Liabilities	$2.61M	$8.51M	$2.23M	$6.16M	$933.00K
Retained Earnings	-$64.97M	-$70.20M	-$73.18M	-$81.29M	-$83.83M
Shareholders' Equity	$2.80M	-$1.67M	$4.61M	$3.15M	$1.25M
Working Capital	$2.35M	-$2.10M	$4.20M	$3.15M	$1.25M
Net Debt	—	$344.80K	—	—	—

INDP Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$5.05M	-$4.02M	-$2.57M	-$3.19M	-$7.01M
Free Cash Flow	-$5.05M	-$4.02M	-$2.57M	-$3.19M	-$7.01M
Depreciation & Amortisation	$0.00	$0.00	$0.00	$0.00	—
Stock-Based Compensation	$240.89K	$180.76K	$150.61K	$785.81K	$227.18K
Financing Cash Flow	$3.15M	$6.28M	$2.24M	$5.87M	$0.00
Net Change in Cash	-$1.90M	$2.27M	-$332.06K	$2.68M	-$7.01M

Market Snapshot

About

Indaptus Therapeutics, Inc. is a pre-clinical stage biotechnology company developing novel therapeutics for cancer treatment. The company's approach focuses on targeting the tumor microenvironment and cancer metabolism to disrupt cancer cell survival mechanisms. Indaptus is advancing its lead programs through preclinical development with the goal of initiating clinical trials. The company's technology platform aims to identify and exploit cancer-specific vulnerabilities that can be addressed with small molecule or biologic therapies.